CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Minocycline Hydrochloride

· ingredient minocyclineAntiinfectives and antiseptics for local oral treatment· MINOCYCLINE HYDROCHLORIDE 100 mg/1; MINOCYCLINE HYDROCHLORIDE 50 mg/1; MINOCYCLINE HYDROCHLORIDE 75 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.68652
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 8 weeks.

2025-07-232026-05-20

Same-ingredient options by acquisition cost

Other minocycline products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Minocycline hydrochloride$0.36875−$0.31780

Medicare Part D coverage · CY2026

On 122 plan formularies · typical tier 4
Prior auth 0% · Step therapy 5% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.